课题基金 / 基金详情

Investigating lung regeneration and repair pathways in Cystic Fibrosis

Investigating lung regeneration and repair pathways in Cystic Fibrosis
研究囊性纤维化的肺再生和修复途径
批准号:
MR/V030078/1
负责人:
Nicola Jane Robinson
金额:
$22.54万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
囊性纤维化(CF)是一种致命的遗传性疾病,影响着英国超过10,000人和全球70,000人。它是由囊性纤维化基因的两个突变引起的,该基因影响着一种名为CFTR的通道,该通道控制着盐和水在人体大多数器官的细胞内的进出。这种有缺陷的盐分通道会产生粘稠的粘液,并导致肺、肠道和胰腺等多个器官的堵塞。肺病是慢性阻塞性肺疾病健康状况不佳的主要原因,它仍然是一种致命的疾病,因此今天出生的患有慢性阻塞性肺病的儿童预计只能活到47岁。目前治疗晚期慢性肺病的唯一方法是挽救生命的肺移植,但这种选择对许多人来说是不可用的,而且通常慢性肺病患者在等待肺移植时死亡。一种名为CFTR调节剂的新型CF药物的开发现在为许多患者带来了希望。这些药物打开了有缺陷的CFTR通道,允许盐和水的运输,并改善了肺部的粘液阻塞。新的调节剂现在被证明可以改善CF患者的肺功能,但它们不能逆转已经遭受的肺损伤。因此,对于CF患者来说,需要以修复受损的肺为重点的治疗。呼吸道包含自己的干细胞,称为基底细胞,对损伤做出反应,并帮助修复受损组织。基底细胞存在于整个呼吸道,从鼻子一直到肺部的细小呼吸道。当呼吸道表面受损时,基底细胞移动以覆盖该区域,然后转化成各种细胞排列在呼吸道内,促进愈合。当患有CF的人感染时,他们的免疫系统会做出过度反应,释放出破坏呼吸道的刺激性化学物质,他们的白细胞杀灭细菌的效果不如没有CF的人,从而导致他们肺部的损害增加。即使在接受抗生素治疗时,我们也知道慢性阻塞性肺疾病的呼吸道修复方式不同于没有慢性阻塞性肺病的人。它们的基底细胞转化为更多的粘液分泌细胞,而更少的细胞来移动粘液,被称为纤毛细胞。这意味着更多的粘液聚集在他们的呼吸道中,使他们更容易发生胸部感染,感染和错误修复的恶性循环仍在继续。我们现在可以从鼻子中取出基底细胞,并将它们培养在三维凝胶中,形成被称为有机体的微小细胞球。这些结构可以显示,当呼吸道受损时,它们将如何修复。它们甚至在体内产生自己的粘液。目的:我们计划使用我们从CF患者身上采集的基底细胞制成的有机化合物,并用这些细胞来找出为什么CF肺的修复过程不同。我们还将在使用调节剂治疗前后从鼻子中提取细胞,看看这是否会改变基底细胞的行为方式,并有望学习帮助CF肺修复的新方法。潜在的应用:我们希望,随着时间的推移,这将使我们能够开发出治疗方法,通过利用肺自身干细胞的力量,允许CF肺“从内部自我愈合”,并避免CF患者发展为严重的肺部疾病和肺移植。
英文摘要
Cystic Fibrosis (CF) is a lethal inherited condition affecting over 10,000 people in the UK and 70,000 people worldwide. It is caused by having two mutations in the Cystic Fibrosis gene which affects a channel called CFTR that controls the flow of salt and water in and out of cells in most organs of the body. This faulty salt channel creates thick, sticky mucus and causes blockages in multiple organs such as the lungs, the bowel and the pancreas. Lung disease is the main cause of ill health in CF and it remains a deadly condition, such that a child born today with CF is only expected to live until the age of 47. The only present cure for advanced CF lung disease is a life-saving lung transplant, but this option isn't available to many, and often CF patients die whilst awaiting a lung transplant. The development of a new class of CF drugs called CFTR modulators now offers hope to many patients. These drugs open up the faulty CFTR channel allowing salt and water transport and an improvement in mucus blockage in the lungs. Newer modulators have now been shown to improve lung function in people with CF, but they do not reverse the lung damage that has already been suffered. Therefore, treatments focused on repairing damaged lungs are required for people with CF. The airway contains its own stem cells, called basal cells, that respond to injury and help to repair damaged tissue. Basal cells are present throughout the airway, from the nose all the way to the small airways of the lungs. When the surface of the airway is damaged, basal cells move to cover the area and then transform a variety of cells that line the airway and promote healing. When people with CF get an infection, their immune system responds excessively, releasing harsh chemicals that damage the airways, and their white blood cells are less effective at killing the bacteria than someone without CF, leading to increased damage within their lungs. Even when treated with antibiotics we know that the CF airways don't repair in the same way as people without CF. Their basal cells transform into more mucus secreting cells and fewer cells to move the mucus, known as cilliated cells. This means more mucus collects in their airways, leaving them more prone to chest infections, and a vicious circle of infection and faulty repair continues. We can now take basal cells from the nose and grow these in 3 dimensional gels to form tiny balls of cells called organoids. These structures can show how the airways would repair when damaged. They even create their own mucus on the inside. Aims:We plan to use organoids made from basal cells that we have sampled from people with CF and use these to figure out why the process of repair is different in the CF lung. We will also take cells from the nose before and after treatment with modulator therapy, to see if this changes the way basal cells behave, and hopefully learn new ways by which we can help the CF lung repair. Potential applications:In time, we hope this will allow us to develop treatments that will allow the CF lung to "heal itself from within" by harnessing the power of the lungs own stem cells and avoid the progression of people with CF to severe lung disease and lung transplant.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
SERS microsensors for pH measurements in the lumen and ECM of stem cell derived human airway organoids.
SERS 微传感器,用于测量干细胞衍生的人体气道类器官的管腔和 ECM 中的 pH 值。
DOI: 10.1039/d2cc06582g
发表时间: 2023
期刊: Chemical communications (Cambridge, England)
影响因子: --
作者: [Skinner WH]
通讯作者: Skinner WH
国内基金
海外基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    谢文晖
  • 依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
  • 批准号:
    82371997
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张春富
  • 依托单位:
IL-33调控EOMES+Tr1样细胞分化介导EGFR突变肺癌免疫逃逸的机制研究
脂肪酸合成通过GDF15/IRS2介导胰岛素抵抗促进血管内皮细胞活化导致脓毒症肺损伤的机制研究
  • 批准号:
    82372203
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李然然
  • 依托单位: